Pharmaceutical

An omnibus survey conducted in the UK, Germany, Italy and Spain for GSK.

The world of pharma business insight is likely to change as it embraces a multi-data source reality.

One in five Britons find it acceptable to bulk buy personal hygiene products amid coronavirus pandemic while a majority think it’s unacceptable to bulk buy at all.

Today, patient centricity is not only well documented in corporate visions and missions, it’s at the top of many pharmaceutical company agendas. Clearly, there is both a need for it and an appetite for it among those best placed to make it happen. The question that remains for pharma and biotechs is how best to be patient-centric.

Today at the eyeforpharma Philadelphia conference, The Aurora Project announces the release of its 2nd Annual Patient-Centric Benchmark Survey.

Trust and reputation are essential considerations for companies seeking to deliver AI technology in healthcare. It is vital to demonstrate transparency, and have meaningful engagement with the influencers that help shape public opinion, as well as the stakeholders that are instrumental in determining the regulatory response to new uses of personal data.

Drug pricing has long been a key reputational issue for the pharmaceutical industry in the eyes of consumers. In light of recent media coverage of this issue, it is unlikely that perceptions are going to shift any time soon. However, many senior stakeholder groups are positive about the future of Pharmaceuticals.

Trust in scientific information and how the major pharmaceutical companies compare with the NHS.